Portal de Periódicos da CAPES

Chapter 6.2. Immune Function–related Liver Disease and ESPGHAN's Contribution to the Advancement of Science in the Last 3 Decades

2018; Lippincott Williams & Wilkins; Volume: 66; Issue: S1 Linguagem: Inglês

10.1002/j.1536-4801.2018.tb00054.x

1536-4801

Anil Dhawan, Giorgina Mieli‐Vergani, Diego Vergani, Nedim Hadžić, Giuseppe Maggiore,

Hepatitis B Virus Studies

Journal of Pediatric Gastroenterology and NutritionVolume 66, Issue S1 p. S122-S128 Supplement Chapter 6.2. Immune Function–related Liver Disease and ESPGHAN's Contribution to the Advancement of Science in the Last 3 Decades Anil Dhawan, Anil DhawanSearch for more papers by this authorGiorgina Mieli-Vergani, Giorgina Mieli-VerganiSearch for more papers by this authorDiego Vergani, Diego VerganiSearch for more papers by this authorNedim Hadzic, Nedim HadzicSearch for more papers by this authorGiuseppe Maggiore, Giuseppe MaggioreSearch for more papers by this author Anil Dhawan, Anil DhawanSearch for more papers by this authorGiorgina Mieli-Vergani, Giorgina Mieli-VerganiSearch for more papers by this authorDiego Vergani, Diego VerganiSearch for more papers by this authorNedim Hadzic, Nedim HadzicSearch for more papers by this authorGiuseppe Maggiore, Giuseppe MaggioreSearch for more papers by this author First published: 01 April 2018 https://doi.org/10.1002/j.1536-4801.2018.tb00054.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1.Maggiore G, Bernard O, Homberg JC, et al. Liver disease associated with anti-liver-kidney microsome antibody in children. J Pediatr 1986; 108: 399–404. 10.1016/S0022-3476(86)80880-0 CASPubMedWeb of Science®Google Scholar 2.Codoner-Franch P, Bernard O, Maggiore G, et al. Clinical and immunological heterogeneity of anti-liver-kidney microsome antibody-positive autoimmune hepatitis in children. J Pediatr Gastroenterol Nutr 1989; 9: 436–440. 10.1002/j.1536-4801.1989.tb09899.x CASPubMedWeb of Science®Google Scholar 3.Maggiore G, Porta G, Bernard O, et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 1990; 116: 280–282. 10.1016/S0022-3476(05)82892-6 CASPubMedWeb of Science®Google Scholar 4.Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541–547. 10.1002/hep.510250308 CASPubMedWeb of Science®Google Scholar 5.Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544–553. 10.1053/jhep.2001.22131 CASPubMedWeb of Science®Google Scholar 6.Gregorio GV, Portmann B, Mowat AP, et al. A 12-year-old girl with antimitochondrial antibody-positive autoimmune hepatitis. J Hepatol 1997; 27: 751–754. 10.1016/S0168-8278(97)80093-1 CASPubMedWeb of Science®Google Scholar 7.Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis. Lancet 1956; 27: 1323–1326. 10.1016/S0140-6736(56)91483-0 Google Scholar 8.Johnson GD, Holborow EJ, Glynn LE. Antibody to smooth muscle in patients with liver disease. Lancet 1965; 2: 878–879. 10.1016/S0140-6736(65)92505-5 CASPubMedWeb of Science®Google Scholar 9.Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of autoimmune hepatitis. Hepatology 1987; 7: 1333–1339. 10.1002/hep.1840070626 CASPubMedWeb of Science®Google Scholar 10.Bridoux-Henno L, Maggiore G, Johanet C, et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004; 2: 825–830. 10.1016/S1542-3565(04)00354-4 PubMedWeb of Science®Google Scholar 11.Senaldi G, Portmann B, Mowat AP, et al. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child 1992; 67: 1447–1453. 10.1136/adc.67.12.1447 CASPubMedWeb of Science®Google Scholar 12.Nouri-Aria KT, Lobo-Yeo A, Vergani D, et al. T suppressor cell function and number in children with liver disease. Clin Exp Immunol 1985; 61: 283–289. CASPubMedWeb of Science®Google Scholar 13.Nouri-Aria KT, Donaldson PT, Hegarty JE, et al. HLA A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis. J Hepatol 1985; 1: 235–241. 10.1016/S0168-8278(85)80051-9 CASPubMedWeb of Science®Google Scholar 14.Vento S, Hegarty JE, Bottazzo G, et al. Antigen specific suppressor cell function in autoimmune chronic active hepatitis. Lancet 1984; 1: 1200–1204. 10.1016/S0140-6736(84)91691-X CASPubMedWeb of Science®Google Scholar 15.Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004; 41: 31–37. 10.1016/j.jhep.2004.03.008 CASPubMedWeb of Science®Google Scholar 16.Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008; 47: 581–591. 10.1002/hep.22071 CASPubMedWeb of Science®Google Scholar 17.Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006; 176: 4484–4491. 10.4049/jimmunol.176.7.4484 CASPubMedWeb of Science®Google Scholar 18.Shevach EM, McHugh RS, Piccirillo CA, et al. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001; 182: 58–67. 10.1034/j.1600-065X.2001.1820104.x CASPubMedWeb of Science®Google Scholar 19.Ferri S, Longhi MS, De Molo C, et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology 2010; 52: 999–1007. 10.1002/hep.23792 CASPubMedWeb of Science®Google Scholar 20.Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 2005; 25: 63–71. 10.1016/j.jaut.2005.05.001 CASPubMedWeb of Science®Google Scholar 21.Grant CR, Liberal R, Holder BS, et al. Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology 2014; 59: 1007–1015. 10.1002/hep.26583 CASPubMedWeb of Science®Google Scholar 22.Liberal R, Grant CR, Holder BS, et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway. Hepatology 2012; 56: 677–686. 10.1002/hep.25682 CASPubMedWeb of Science®Google Scholar 23.Lobo-Yeo A, Senaldi G, Portmann B, et al. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology 1990; 12: 224–232. 10.1002/hep.1840120208 CASPubMedWeb of Science®Google Scholar 24.Lobo-Yeo A, Alviggi L, Mieli-Vergani G, et al. Preferential activation of helper/inducer T lymphocytes in autoimmune chronic active hepatitis. Clin Exp Immunol 1987; 67: 95–104. CASPubMedWeb of Science®Google Scholar 25.Gueguen M, Meunier-Rotival M, Bernard O, et al. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 1988; 168: 801–806. 10.1084/jem.168.2.801 CASPubMedWeb of Science®Google Scholar 26.Ma Y, Bogdanos DP, Hussain MJ, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006; 130: 868–882. 10.1053/j.gastro.2005.12.020 CASPubMedWeb of Science®Google Scholar 27.Longhi MS, Hussain MJ, Bogdanos DP, et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007; 46: 472–484. 10.1002/hep.21658 CASPubMedWeb of Science®Google Scholar 28.Manns MP, Griffin KJ, Sullivan KF, et al. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 1370–1378. 10.1172/JCI115443 CASPubMedWeb of Science®Google Scholar 29.Kerkar N, Choudhuri K, Ma Y, et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003; 170: 1481–1489. 10.4049/jimmunol.170.3.1481 CASPubMedWeb of Science®Google Scholar 30.Jensen DM, McFarlane IG, Portmann BS, et al. Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med 1978; 299: 1–7. 10.1056/NEJM197807062990101 CASPubMedWeb of Science®Google Scholar 31.McFarlane BM, McSorley CG, Vergani D, et al. Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol 1986; 3: 196–205. 10.1016/S0168-8278(86)80026-5 CASPubMedWeb of Science®Google Scholar 32.Ma Y, Gaken J, McFarlane BM, et al. Alcohol dehydrogenase: a target of humoral autoimmune response in liver disease. Gastroenterology 1997; 112: 483–492. 10.1053/gast.1997.v112.pm9024302 CASPubMedWeb of Science®Google Scholar 33.Vergani D, Mieli-Vergani G, Mondelli M, et al. Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver 1987; 7: 307–315. 10.1111/j.1600-0676.1987.tb00361.x CASPubMedWeb of Science®Google Scholar 34.Mieli-Vergani G, Vergani D, Jenkins PJ, et al. Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis. Clin Exp Immunol 1979; 38: 16–21. PubMedWeb of Science®Google Scholar 35.Wen L, Ma Y, Bogdanos DP, et al. Pediatric autoimmune liver diseases the molecular basis of humoral and cellular immunity. Curr Mol Med 2001; 1: 379–389. 10.2174/1566524013363672 CASPubMedGoogle Scholar 36.Wen L, Peakman M, Lobo-Yeo A, et al. T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet 1990; 336: 1527–1530. 10.1016/0140-6736(90)93306-A CASPubMedWeb of Science®Google Scholar 37.Lohr H, Manns M, Kyriatsoulis A, et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 1991; 84: 297–302. 10.1111/j.1365-2249.1991.tb08164.x CASPubMedWeb of Science®Google Scholar 38.Lohr H, Treichel U, Poralla T, et al. Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprotein receptor in vitro. Clin Exp Immunol 1992; 88: 45–49. 10.1111/j.1365-2249.1992.tb03037.x CASPubMedWeb of Science®Google Scholar 39.Lohr H, Fleischer B, Michel G, et al. Hepatitis C virus antibody secretion in vitro by peripheral blood lymphocytes. J Hepatol 1992; 14: 112–117. 10.1016/0168-8278(92)90139-G CASPubMedWeb of Science®Google Scholar 40.Zhao L, Tang Y, You Z, et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One 2011; 6: e18909. 10.1371/journal.pone.0018909 CASPubMedWeb of Science®Google Scholar 41.Lapierre P, Hajoui O, Homberg JC, et al. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999; 116: 643–649. 10.1016/S0016-5085(99)70186-1 CASPubMedWeb of Science®Google Scholar 42.Yuksel M, Wang Y, Tai N, et al. A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology 2015; 62: 1536–1550. 10.1002/hep.27998 CASPubMedWeb of Science®Google Scholar 43.el-Shabrawi M, Wilkinson ML, Portmann B, et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987; 92 (5 pt 1): 1226–1235. 10.1016/S0016-5085(87)91082-1 CASPubMedWeb of Science®Google Scholar 44.Underhill J, Ma Y, Bogdanos DP, et al. Different immunogenetic background in autoimmune hepatitis type 1, type and autoimmune sclerosing cholangitis. J Hepatol 2002; 36 (suppl 1): 156A. 10.1016/S0168-8278(02)80564-5 Web of Science®Google Scholar 45.Scalori A, Heneghan M, Hadzic N, et al. Outcome and survival in childhood onset autoimmune sclerosing cholangitis and autoimmune hepatitis: a 13-year follow up study. Hepatology 2007; 46S: 555A. Google Scholar 46.Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998; 351: 409–413. 10.1016/S0140-6736(97)06478-7 CASPubMedWeb of Science®Google Scholar 47.Vergani D, Mieli-Vergani G. Autoimmunity after liver transplantation. Hepatology 2002; 36: 271–276. 10.1053/jhep.2002.35339 CASPubMedWeb of Science®Google Scholar 48.Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004; 40: 3–7. 10.1016/j.jhep.2003.10.022 PubMedWeb of Science®Google Scholar 49.Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007; 7: 955–963. 10.1111/j.1600-6143.2006.01717.x CASPubMedWeb of Science®Google Scholar 50.Evans H. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006; 43: 1109–1117. 10.1002/hep.21152 PubMedWeb of Science®Google Scholar 51.Bernard O, Hadchouel M, Scotto J, et al. Severe giant cell hepatitis with autoimmune hemolytic anemia in early childhood. J Pediatr 1981; 99: 704–711. 10.1016/S0022-3476(81)80388-5 CASPubMedWeb of Science®Google Scholar 52.Maggiore G, Sciveres M, Fabre M, et al. Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children. J Pediatr 2011; 159: 127–132. e1. 10.1016/j.jpeds.2010.12.050 PubMedWeb of Science®Google Scholar 53.Hadzic N, Portmann B, Lewis I, et al. Coombs positive giant cell hepatitis--a new feature of Evans’ syndrome. Arch Dis Child 1998; 78: 397–398. 10.1136/adc.78.4.e395 CASPubMedWeb of Science®Google Scholar 54.Miloh T, Manwani D, Morotti R, et al. Giant cell hepatitis and autoimmune hemolytic anemia successfully treated with rituximab. J Pediatr Gastroenterol Nutr 2007; 44: 634–636. 10.1097/MPG.0b013e31802e9739 PubMedWeb of Science®Google Scholar 55.Rovelli A, Corti P, Beretta C, et al. Alemtuzumab for giant cell hepatitis with autoimmune hemolytic anemia. J Pediatr Gastroenterol Nutr 2007; 45: 596–599. 10.1097/MPG.0b013e318033169f PubMedWeb of Science®Google Scholar 56.Melendez HV, Rela M, Baker AJ, et al. Liver transplant for giant cell hepatitis with autoimmune haemolytic anaemia. Arch Dis Child 1997; 77: 249–251. 10.1136/adc.77.3.249 CASPubMedWeb of Science®Google Scholar 57.Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998–1005. 10.1002/hep.1840180435 CASPubMedWeb of Science®Google Scholar 58.Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929–938. 10.1016/S0168-8278(99)80297-9 CASPubMedWeb of Science®Google Scholar 59.Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169–176. 10.1002/hep.22322 PubMedWeb of Science®Google Scholar Volume66, IssueS1April 2018Pages S122-S128 ReferencesRelatedInformation